echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > CDE issued 5 guiding principles involving traditional Chinese medicine, improved new drugs, innovative drugs, etc.

    CDE issued 5 guiding principles involving traditional Chinese medicine, improved new drugs, innovative drugs, etc.

    • Last Update: 2022-01-25
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
           On January 7, CDE's official website released 5 guidelines, involving the study of samples for toxicology research of new traditional Chinese medicines, the clinical pharmacokinetics research of modified-release preparations of new drugs, and the research on human bioavailability and bioequivalence of innovative drugs
    .
    The details are as follows: Under the deployment of the State Drug Administration, the Center for Drug Evaluation organized the formulation of the "Technical Guidelines for the Study of Samples for Toxicology Research of New Chinese Medicines (for Trial Implementation)" (see attachment)

    .
    In accordance with the requirements of the "Notice of the General Department of the State Food and Drug Administration on Issuing the Procedures for Issuing the Technical Guiding Principles for Drugs" (Yijian Zongyaoguan [2020] No.
    9), and with the approval of the State Food and Drug Administration, it is hereby issued from the date of issuance to be implemented

    .
    Attachments: 1.
    Technical Guidelines for the Study of Samples for Toxicology Research of New Chinese Medicines (Trial) Under the deployment of the Supervision Administration, the Center for Drug Evaluation organized the revision of the "Technical Guidelines for Drug Non-Clinical Dependence Research"

    .
    In accordance with the requirements of the "Notice of the General Department of the State Food and Drug Administration on Issuing the Procedures for Issuing the Technical Guiding Principles for Drugs" (Yijian Zongyaoguan [2020] No.
    9), and with the approval of the State Food and Drug Administration, it is hereby issued from the date of issuance to be implemented

    .
    The "Technical Guiding Principles for Drug Non-Clinical Dependence Research" issued by the former State Food and Drug Administration in 2007 is abolished

    .
    Attachment: Technical Guiding Principles for Drug Non-Clinical Dependence Research In order to further encourage and guide the rational and standardized pharmacokinetic research of modified-release preparations in improved new drugs and provide technical specifications for reference, the Center for Drug Evaluation organized the formulation of the "Improved New Drugs".
    Technical Guiding Principles for Clinical Pharmacokinetic Research of Modified Release Preparations (see appendix)

    .
    In accordance with the requirements of the "Notice of the General Department of the State Food and Drug Administration on Issuing the Procedures for Issuing the Technical Guiding Principles for Drugs" (Yijian Zongyaoguan [2020] No.
    9), and with the approval of the State Food and Drug Administration, it is hereby issued from the date of issuance to be implemented

    .
    Attachment: Technical Guiding Principles for Clinical Pharmacokinetics Research of Modified Release Drugs of Modified New Drugs Under the deployment of the Supervision and Administration Bureau, the Center for Drug Evaluation organized the formulation of the "Technical Guidelines for Human Bioavailability and Bioequivalence Research of Innovative Drugs" (see attachment)

    .
    In accordance with the requirements of the "Notice of the General Department of the State Food and Drug Administration on Issuing the Procedures for Issuing the Technical Guiding Principles for Drugs" (Yijian Zongyaoguan [2020] No.
    9), it is hereby issued with the approval of the State Food and Drug Administration

    .
    Attachment: Technical Guiding Principles for Human Bioavailability and Bioequivalence Research of Innovative Drugs In order to clarify the relevant technical requirements for random allocation design and implementation in clinical trial research, the Center for Drug Evaluation organized the formulation of the "Guiding Principles for Random Allocation of Drug Clinical Trials (Trial)" (see attachment)

    .
    In accordance with the requirements of the "Notice of the General Department of the State Food and Drug Administration on Issuing the Procedures for Issuing the Technical Guiding Principles for Drugs" (Yijian Zongyaoguan [2020] No.
    9), and with the approval of the State Food and Drug Administration, it is hereby issued from the date of issuance to be implemented

    .
    Annex: Guidelines for random allocation of drug clinical trials (trial)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.